The molecular genetic landscape of pancreatic cancer has been studied by whole-genome and exome sequencing, and KRAS, CDKN2A, TP53, and SMAD4 are frequently reported as mutated in pancreatic cancer [33–37]. This evidence concerns the gene TP53 and familial pancreatic carcinoma.